gip/glp-1 drugs The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology GLP-1 Medications: Everything You Need

Gao Y, Ottaway N, Schriever SC, Legutko B, Garcia-Caceres C, de la Fuente E, et al

They reduce de novo lipogenesis by inhibiting transcription factor sterol regulatory element-binding protein 1c (SREBP-1c), which is a master regulator of fatty acid synthesis ( TABLE 1 Therapeutic actions of GLP-1 receptor agonists in liver disease: summary of experimental and clinical findings

C., Edmondson, S., Feeney, W

In PCOS-related trials, even with low starting doses and gradual titration, discontinuation rates of approximately 5%15% are frequently observed (125, 128)

SM has received grants from Boehringer Ingelheim and Novo Nordisk, personal fees for advisory boards from Aventis, Boehringer Ingelheim, MSD and Novo Nordisk, and personal fees for lectures from Novo Nordisk